Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - Sanara MedTech Inc. | smti_ex991.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): October 29,
2020
SANARA MEDTECH INC.
(Exact name of registrant as specified in its
charter)
|
Texas
|
000-11808
|
59-2219994
|
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(I.R.S.
Employer Identification No.)
|
|
1200
Summit Avenue, Suite 414 Fort
Worth, Texas
|
76102
|
|
(Address
of principal executive offices)
|
(zip
code)
|
Registrant’s telephone number, including area code:
(817)-529-2300
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Securities registered pursuant Section 12(b) of the Act:
None
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
--
|
--
|
--
|
Indicate
by check mark whether the registrant is an emerging growth company
as defined in in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this
chapter).
Emerging growth company ☐
If an emerging growth company, indicate by
checkmark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the
Exchange Act. ☐
Item
7.01 Regulation FD Disclosure.
On
October 29, 2020, Sanara MedTech Inc. issued a press release
announcing its uplisting to The Nasdaq Capital Market. A copy of
the press release is
attached as Exhibit 99.1 to this Current Report on Form 8-K and is
incorporated by reference herein.
The
information in Item 7.01 of this Current Report on Form 8-K,
including Exhibit 99.1, is being furnished and shall not be deemed
“filed” for the purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, or otherwise subject
to the liabilities under that Section. Further, the information in
Item 7.01 of this Current Report on Form 8-K, including Exhibit
99.1, shall not be deemed to be incorporated by reference into the
filings of the Company under the Securities Act of 1933, as
amended. Item 7.01 of this Current Report on Form 8-K will not be
deemed an admission as to the materiality of any information in
this Current Report on Form 8-K that is required to be disclosed
solely by Regulation FD.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits:
|
Exhibit No.
|
Description
|
|
Press Release
issued October 29, 2020 (furnished pursuant to Item
7.01).
|
SIGNATURE
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Company
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
Sanara
MedTech Inc.
|
|
|
|
|
|
|
|
|
Date:
October
29, 2020
|
By:
|
/s/ Michael D.
McNeil
|
|
|
|
|
Name: Michael D.
McNeil
|
|
|
|
|
Title:
Chief
Financial Officer
|
|